Papers/PMID:37037891
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.
Scientific reports2023The record
10 findings · 1 compound · 10 endpoints · 6 null
What it reported
How to read these marksWhat moved
4 findings
curcumin — decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The overall pooling of data indicated that curcumin supplementation was significantly associated with reduced AST with MD (95% CI) of −3.90 (−5.97, −1.82) units/L, although high heterogeneity was observed (I2 = 73.9%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 15 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -3.9 mean difference, 95% CI -5.97 to -1.82
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×5“Twelve studies assessed reduction of FBS indicating curcumin supplementation was associated with a significant reduction in FBS, with MD (95% CI) of −2.05 (−3.08, −1.01) mg/dL, I2 = 0%, see Supplementary Appendix O.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 12 RCTs; glycaemic indices were an additional (secondary) outcome of this review, not a liver endpoint
Effect -2.05 mean difference, 95% CI -3.08 to -1.01
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×7“Thirteen studies assessed reduction of BMI indicating curcumin supplementation was effective in lowering BMI with MD (95% CI) of −0.34 (−0.62, −0.05) kg/m2; I2 = 62.7%, see Supplementary Appendix Q.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 13 RCTs; BMI was an additional (secondary) outcome of this review
Effect -0.34 mean difference, 95% CI -0.62 to -0.05
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The overall pooling indicated that curcumin supplementation was significantly associated with reduced ALT [MD (95% CI) of −5.61 (−9.37, −1.85) units/L] with moderate heterogeneity observed (I2 = 64.3%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 14 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -5.61 mean difference, 95% CI -9.37 to -1.85
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
What did not
6 findings
curcumin — no detected effect on diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.02 mean difference, 95% CI -0.55 to 0.52
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on serum alkaline phosphatase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“There was no significant association between curcumin supplement and ALP [MD (95% CI) of −8.88 (−24.68, 6.93) units/L].”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 6 RCTs, all using bioavailability-enhanced curcumin forms; liver enzymes were a primary outcome of interest
Effect -8.88 mean difference, 95% CI -24.68 to 6.93
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.29 mean difference, 95% CI -0.91 to 0.34
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“However, curcumin was not significantly associated with HbA1c based on pooling three included studies with MD (95% CI) of −0.24 (−0.66, 0.18) %, I2 = 85.8%, see Supplementary Appendix P.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 3 RCTs pooled; glycaemic indices were an additional (secondary) outcome of this review
Effect -0.24 mean difference, 95% CI -0.66 to 0.18
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×8“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 10 trials
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×4“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 11 trials
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink